Republic First Bancorp, Inc. (FRBK) Forms $8.30 Double Bottom; Cardiome Pharma Ord (CRME) Sellers Increased By 15.66% Their Shorts

Republic First Bancorp, Inc. (FRBK) formed double bottom with $7.55 target or 9.00% below today’s $8.30 share price. Republic First Bancorp, Inc. (FRBK) has $473.02M valuation. It closed at $8.3 lastly. It is down 95.56% since February 13, 2017 and is uptrending. It has outperformed by 78.86% the S&P500.

Cardiome Pharma Corporation Ord (NASDAQ:CRME) had an increase of 15.66% in short interest. CRME’s SI was 130,000 shares in February as released by FINRA. Its up 15.66% from 112,400 shares previously. With 102,200 avg volume, 1 days are for Cardiome Pharma Corporation Ord (NASDAQ:CRME)’s short sellers to cover CRME’s short positions. The SI to Cardiome Pharma Corporation Ord’s float is 0.56%. The stock increased 5.68% or $0.079 during the last trading session, reaching $1.469. About 46,769 shares traded. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 11.02% since February 13, 2017 and is downtrending. It has underperformed by 27.72% the S&P500.

Among 6 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cardiome Pharma Corp had 15 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, December 15 by Mackie. Canaccord Genuity maintained the shares of CRME in report on Monday, August 21 with “Buy” rating. H.C. Wainwright maintained the shares of CRME in report on Tuesday, August 22 with “Buy” rating. LB Securities reinitiated it with “Buy” rating and $12.50 target in Friday, August 14 report. Brean Capital maintained Cardiome Pharma Corp. (NASDAQ:CRME) rating on Friday, March 11. Brean Capital has “Buy” rating and $10 target. The rating was downgraded by Zacks to “Buy” on Tuesday, August 11. H.C. Wainwright initiated Cardiome Pharma Corp. (NASDAQ:CRME) rating on Wednesday, June 1. H.C. Wainwright has “Buy” rating and $9.50 target. The stock has “Hold” rating by Zacks on Wednesday, August 26. On Wednesday, November 22 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock has “Buy” rating by Canaccord Genuity on Wednesday, November 15.

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company has market cap of $51.33 million. It offers BRINAVESS ) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It currently has negative earnings. The firm also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension.

Investors sentiment increased to 1.09 in 2017 Q3. Its up 0.26, from 0.83 in 2017Q2. It improved, as 2 investors sold Cardiome Pharma Corp. shares while 9 reduced holdings. 7 funds opened positions while 5 raised stakes. 13.54 million shares or 10.92% less from 15.20 million shares in 2017Q2 were reported. Putnam Invests Lc has invested 0.02% in Cardiome Pharma Corp. (NASDAQ:CRME). Fincl Bank Of Montreal Can has invested 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). Bank & Trust Of Nova Scotia holds 10 shares or 0% of its portfolio. Knott David M reported 0.12% in Cardiome Pharma Corp. (NASDAQ:CRME). Virtu Fincl Lc has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Maryland-based Rock Springs Capital Mngmt Limited Partnership has invested 0.12% in Cardiome Pharma Corp. (NASDAQ:CRME). Jpmorgan Chase & Company reported 158,697 shares or 0% of all its holdings. Ardsley Advisory Prns holds 0.01% or 36,200 shares in its portfolio. Gru Incorporated One Trading Lp reported 917 shares. Morgan Stanley reported 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Alphaone Ltd Liability Corporation invested in 0.34% or 600,625 shares. Clough Lp stated it has 2.88 million shares. Toronto Dominion Bancorp reported 84 shares. Valley Advisers owns 50 shares. Jefferies Lc has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME).